Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail
?
-

Resources for You

-

RiaSTAP

Proper Name: Fibrinogen Concentrate (Human)
Tradename: RiaSTAP
Manufacturer: CSL Behring GmbH, License # 1765

Date: January 16, 2009
Indication: For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia).
January 16, 2009 Approval Letter
Press Release: FDA Approves RiaSTAP for Treatment of Bleeding in Patients with Rare Genetic Defect - January 16, 2009
Summary Basis for Regulatory Action (PDF - 689 KB)


Approval History, Letters, Reviews, and Related Documents

 

Contact FDA

(800) 835-4709
(301) 827-1800
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

1401 Rockville Pike

Suite 200N/HFM-47

Rockville, MD 20852-1448
-
-